Inflarx N.V. (IFRX) — SEC Filings

Q: What are the key financial highlights for Inflarx N.V.?

Key financial highlights for Inflarx N.V. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Inflarx N.V.?

Key executives at Inflarx N.V. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Inflarx N.V. stock?

Risk factors for Inflarx N.V. (IFRX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Inflarx N.V.?

Forward-looking statements and predictions from Inflarx N.V. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Inflarx N.V.. Recent 6-K filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Inflarx N.V. on SEC EDGAR

Overview

Inflarx N.V. (IFRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 23, 2026: InflaRx N.V. filed a Form 6-K on April 23, 2026, reporting as a foreign issuer. The filing includes a 6-K document, an exhibit (EX-99.1), and a graphic image. The company's business address is WINZERLAER STR. 2, JENA 2M 07745.

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 5 bullish, 3 bearish, 24 neutral. The dominant filing sentiment for Inflarx N.V. is neutral.

Filing Type Overview

Inflarx N.V. (IFRX) has filed 29 6-K, 2 20-F, 1 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (32)

InflaRx N.V. Files 6-K Report — 6-K · Apr 23, 2026 Risk: low
InflaRx N.V. filed a Form 6-K on April 23, 2026, reporting as a foreign issuer. The filing includes a 6-K document, an exhibit (EX-99.1), and a graphic image. T
InflaRx N.V. Files Form 6-K — 6-K · Apr 9, 2026 Risk: low
InflaRx N.V. filed a Form 6-K on April 9, 2026, reporting as a foreign issuer. The filing includes a press release dated April 9, 2026, and associated graphic f
InflaRx Updates Vilobelimab Phase 3 Data After Trial Termination — 6-K · Dec 30, 2025 Risk: medium
On December 30, 2025, InflaRx N.V. provided an update on Phase 3 data analyses for its drug vilobelimab in treating pyoderma gangrenosum. This follows the earli
6-K Filing — 6-K · Nov 10, 2025
InflaRx N.V. Faces Nasdaq Bid Price Non-Compliance — 6-K · Sep 12, 2025 Risk: medium
InflaRx N.V. filed a 6-K on September 12, 2025, to update on its non-compliance with Nasdaq's minimum bid price requirement. The company was notified on July 11
InflaRx N.V. Files 6-K, Incorporates Exhibits — 6-K · Aug 7, 2025 Risk: low
InflaRx N.V. filed a Form 6-K on August 7, 2025, reporting information for the month of August 2025. This filing includes exhibits 99.1 and 99.2, which are inco
InflaRx Faces Nasdaq Delisting Threat Over Low Share Price — 6-K · Jul 14, 2025 Risk: high
InflaRx N.V. received a written notice from Nasdaq on July 11, 2025, stating that its ordinary shares have closed below the $1.00 minimum bid price requirement
InflaRx N.V. Changes Independent Auditor to KPMG — 6-K · Jun 27, 2025 Risk: low
On June 26, 2025, InflaRx N.V. announced a change in its independent registered public accounting firm. The company has engaged KPMG AG Wirtschaftsprüfungsgesel
InflaRx Halts Phase 3 Trial for Vilobelimab Due to Futility — 6-K · May 28, 2025 Risk: high
On May 28, 2025, InflaRx N.V. announced that the Independent Data Monitoring Committee recommended stopping their Phase 3 trial for vilobelimab in pyoderma gang
InflaRx N.V. Files 6-K for Registration Statement Incorporation — 6-K · May 7, 2025 Risk: low
InflaRx N.V. filed a Form 6-K on May 7, 2025, to incorporate by reference Exhibits 99.1 and 99.2 into its existing registration statements on Form S-8 (File Nos
InflaRx N.V. Reports 2024 Annual Meeting Results — 6-K · Apr 24, 2025 Risk: low
InflaRx N.V. held its Annual General Meeting of Shareholders on April 24, 2025. The primary agenda item was the adoption of the Dutch statutory annual accounts
InflaRx N.V. Announces Annual Shareholder Meeting — 6-K · Apr 3, 2025 Risk: low
InflaRx N.V. filed a Form 6-K on April 3, 2025, to announce its annual general meeting of shareholders scheduled for April 24, 2025. The company made certain ma
InflaRx N.V. Files 2024 Annual Report — 20-F · Mar 20, 2025 Risk: low
InflaRx N.V. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, previously known as Fireman B.V. until June 6, 2017,
InflaRx N.V. Reports 2024 Results and Milestones — 6-K · Mar 20, 2025 Risk: low
On March 20, 2025, InflaRx N.V. (the "Company") issued a press release reporting its full-year 2024 results and highlighting key achievements and expected miles
InflaRx N.V. Files 6-K for Share Offering — 6-K · Feb 18, 2025 Risk: medium
On February 13, 2025, InflaRx N.V. entered into an Underwriting Agreement with Guggenheim Securities, LLC, as representative of the underwriters, for an offerin
InflaRx N.V. Gets EU Approval for GOHIBIC® for ARDS — 6-K · Jan 15, 2025 Risk: medium
On January 15, 2025, InflaRx N.V. announced that the European Commission has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilob
InflaRx Doses First Patient in INF904 Phase 2a Study — 6-K · Dec 20, 2024 Risk: medium
On December 20, 2024, InflaRx N.V. announced that the first patient has been dosed in its Phase 2a basket study for its oral C5aR inhibitor, INF904. This multi-
InflaRx N.V. Gets Positive CHMP Opinion for GOHIBIC® — 6-K · Nov 15, 2024 Risk: medium
On November 15, 2024, InflaRx N.V. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a posit
InflaRx N.V. Files 6-K, Incorporates Exhibits — 6-K · Nov 8, 2024 Risk: low
InflaRx N.V. filed a Form 6-K on November 8, 2024, to incorporate by reference certain exhibits into its existing registration statements on Form S-8 and Form F
InflaRx Files 6-K, Incorporates Exhibits into S-8 Filings — 6-K · Aug 8, 2024 Risk: low
InflaRx N.V. filed a Form 6-K on August 8, 2024, reporting information for the month of August 2024. The filing includes exhibits 99.1 and 99.2, which are incor
InflaRx N.V. Launches At-The-Market Share Offering — 6-K · Jun 28, 2024 Risk: medium
On June 28, 2024, InflaRx N.V. entered into a Sales Agreement with Leerink Partners LLC to conduct an "at-the-market" offering of its ordinary shares. This agre
InflaRx's GOHIBIC Tapped for BARDA ARDS Trial — 6-K · Jun 24, 2024 Risk: medium
On June 24, 2024, InflaRx N.V. announced that its GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA)
InflaRx N.V. Highlights Promise of INF904 at R&D Event — 6-K · Jun 5, 2024 Risk: low
On June 5, 2024, InflaRx N.V. hosted a virtual R&D event to highlight the potential of its drug candidate INF904. The company presented its corporate presentati
InflaRx N.V. Presents COVID-19 Trial Synergy Data — 6-K · May 21, 2024 Risk: medium
On May 21, 2024, InflaRx N.V. announced new analysis from its PANAMO Phase III trial for severe COVID-19. The analysis suggests potential synergy between their
InflaRx N.V. 6-K Filing Incorporates Exhibits — 6-K · May 8, 2024 Risk: low
InflaRx N.V. filed a Form 6-K on May 8, 2024, to report information for the month of May 2024. The filing indicates that Exhibits 99.1 and 99.2 are incorporated
InflaRx N.V. Approves 2023 Annual Accounts — 6-K · Apr 25, 2024 Risk: low
InflaRx N.V. held its Annual General Meeting of Shareholders on April 25, 2024. Shareholders approved the adoption of the Dutch statutory annual accounts for th
InflaRx N.V. Announces Annual Shareholder Meeting — 6-K · Apr 4, 2024 Risk: low
InflaRx N.V. filed a Form 6-K on April 4, 2024, to announce its annual general meeting of shareholders scheduled for April 25, 2024. The company also made certa
InflaRx N.V. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2023 — 20-F · Mar 21, 2024 Risk: low
InflaRx N.V. (IFRX) filed a Foreign Annual Report (20-F) with the SEC on March 21, 2024. InflaRx N.V. filed its annual report on Form 20-F for the fiscal year e
InflaRx Reports 2023 Results, Pipeline Updates — 6-K · Mar 21, 2024 Risk: medium
On March 21, 2024, InflaRx N.V. reported its full-year 2023 financial and operating results. The company provided updates on its immuno-dermatology pipeline, sp
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
InflaRx Launches GOHIBIC Commitment Program to Broaden Patient Access — 6-K · Jan 25, 2024
InflaRx N.V. (Nasdaq: IFRX) announced on January 25, 2024, the initiation of "The InflaRx Commitment Program" for its drug GOHIBIC® (vilobelimab). This program
InflaRx INF904 Phase I Study Shows Positive Topline Results — 6-K · Jan 4, 2024
InflaRx N.V. announced positive topline results on January 4, 2024, from its Multiple Ascending Dose (MAD) Phase I study for C5aR inhibitor INF904. The study, w

Risk Profile

Risk Assessment: Of IFRX's 28 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Dr. Thomas Taapken

Industry Context

InflaRx N.V. operates in the pharmaceutical preparations industry, focusing on the development of treatments for inflammatory diseases.

Top Tags

drug-development (8) · sec-filing (4) · registration-statement (4) · corporate-governance (4) · clinical-trial (4) · covid-19 (3) · foreign-issuer (2) · nasdaq (2) · regulatory-filing (2) · procedural (2)

Key Numbers

Minimum Bid Price: $1.00 — The threshold below which InflaRx's stock price fell, triggering non-compliance with Nasdaq rules.
Consecutive Business Days: 30 — The duration for which the bid price has remained below the minimum requirement.
patients: 30 — Number of patients analyzed in the interim futility analysis
SEC File Number: 001-38283 — Identifies InflaRx N.V.'s filings with the SEC.
Reporting Period: May 2025 — The month for which this Form 6-K report is filed.
Fiscal Year End: 2024 — The period covered by the annual report.
Filing Date: 20250320 — The date the annual report was submitted to the SEC.
Ordinary Shares Offered: 8,250,000 — This is the total number of shares InflaRx N.V. is offering to the public.
Nominal Value per Share: €0.12 — This is the stated nominal value of each ordinary share being offered.
Outstanding Ordinary Shares: 58,883,272 — As of December 31, 2023

Related Companies

INFX

Frequently Asked Questions

What are the latest SEC filings for Inflarx N.V. (IFRX)?

Inflarx N.V. has 32 recent SEC filings from Jan 2024 to Apr 2026, including 29 6-K, 2 20-F, 1 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of IFRX filings?

Across 32 filings, the sentiment breakdown is: 5 bullish, 3 bearish, 24 neutral. The dominant sentiment is neutral.

Where can I find Inflarx N.V. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Inflarx N.V. (IFRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Inflarx N.V.?

Financial highlights for Inflarx N.V. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for IFRX?

The investment thesis for IFRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Inflarx N.V.?

Key executives identified across Inflarx N.V.'s filings include Dr. Thomas Taapken.

What are the main risk factors for Inflarx N.V. stock?

Of IFRX's 28 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Inflarx N.V.?

Forward guidance and predictions for Inflarx N.V. are extracted from SEC filings as they are enriched.